Participants who stopped GLP-1 medications regained weight at an average rate of 0.4 kg per month, and for those on semaglutide and tirzepatide, the medications most commonly covered in employer benefits today, that rate doubled, with return to baseline weight projected at about 1.5 years
The TRIUMPH-4 Phase 3 data at 68 weeks showed 28.7% average weight loss, confirming that extended treatment does yield additional benefit
Details can be found at: 10.3389/fimmu.2026.1850518
Moreover, it is required for the transport and metabolism of fats and cholesterol within the body, which is important for the healthy support of the endocrine, cardiovascular and hepatic systems
Transdermal administration of resveratrol and curcumin was achieved using cyclodextrin nanospongoid-based hydrogel (CDNS)
This overgrowth leads to many digestive issues like bloating, gas, constipation, and diarrhea